Idorsia Pharmaceuticals Ltd

Actelion Pharmaceuticals Ltd

Davide Pozzi

Olivier Corminboeuf

Sylvia Richard-Bildstein

Heinz Fretz

Isabelle Lyothier

Thierry Sifferlen

Christoph Boss

Sylvaine Cren

Hervé Siendt

Julien Pothier

Xavier Leroy

Lorenza Wyder Peters

Daniel Bur

Corinna Grisostomi

Herv Siendt

The present invention relates to derivatives of formula (I) wherein (R), R, R, R, R, R, Rand Arare as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

N-substituted indole derivatives as PGE2 receptor modulators

The present invention relates to pyrimidine derivatives of formula (I) wherein (R), R, R, R, R, Rand Arare as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

Pyrimidine derivatives as PGE2 receptor modulators

The present invention relates to phenyl derivatives of formula (I)

Phenyl derivatives as PGE2 receptor modulators

The present invention relates to pyrimidine derivatives of formula (I) wherein (R), R, R, R, R, Rand Arare as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

Pyrimidine derivatives

The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R), R, R, R, R, R, Rand Arare as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

Benzofurane and benzothiophene derivatives as PGE2 receptor modulators

The present invention relates to difluoroethyl-oxazole substituted bridged spiro[2.4] heptane derivatives of formula (I), wherein the substituents at the piperidine ring are in trans-arrangement, their preparation and their use as pharmaceutically active compounds.

Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists

The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R, R, R, R, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Benzimidazolyl-methyl urea derivatives as ALX receptor agonists

The present invention relates to a piperazine substituted bridged spiro[2.4]heptane derivative of formula (I), its preparation and its use as pharmaceutically active compound.

Piperazine substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists

The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a catalyst, wherein the method includes the steps of: (i) reacting the excess monomer(s) with an initiator in a solvent, said initiator being selected from among an amine and an amino alcohol, given that the initiator has at least one primary or secondary amine function; (ii) adding a catalyst, said catalyst being a non-nucleophilic base and including at least one neutral sp2 nitrogen atom; and (iii) neutralizing the reaction mixture. Said novel method is particularly advantageous in that it can be easily monitored and enables better modulation of the polymers, and thus of the properties thereof, than the methods of the prior art. The invention also relates to novel polymers that are obtainable by means of said method.

Bridged Spiro[2.4]heptane ester derivatives

The present invention relates to fluorinated bridged spiro[2.4]heptane derivatives of formula (I), wherein n and Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Growing community of inventors

Allschwil, Switzerland

Davide Pozzi